N/A
Completed N=60
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Source: ClinicalTrials.gov NCT03123263 ↗Enrolled (actual)
60
Serious AEs
3.3%
Results posted
Sep 2019
Primary outcomePrimary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
Summary
This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY LVEF |
65.4; 64.7; 62.2 | <0.0005 sig |
| SECONDARY Number of Participants Hospitalized for Cardiac Issues. |
— | — |
Eligibility Criteria
Inclusion Criteria
- Stage 1,2,3 breast cancer
- Her2+
Exclusion Criteria
- Stage 4 cancer
Data sourced from ClinicalTrials.gov (NCT03123263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.